IL158255A0 - Compositions containing imidazotriazinone for nasal application - Google Patents

Compositions containing imidazotriazinone for nasal application

Info

Publication number
IL158255A0
IL158255A0 IL15825502A IL15825502A IL158255A0 IL 158255 A0 IL158255 A0 IL 158255A0 IL 15825502 A IL15825502 A IL 15825502A IL 15825502 A IL15825502 A IL 15825502A IL 158255 A0 IL158255 A0 IL 158255A0
Authority
IL
Israel
Prior art keywords
imidazotriazinone
compositions containing
nasal application
nasal
application
Prior art date
Application number
IL15825502A
Other languages
English (en)
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of IL158255A0 publication Critical patent/IL158255A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL15825502A 2001-04-12 2002-04-03 Compositions containing imidazotriazinone for nasal application IL158255A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10118306A DE10118306A1 (de) 2001-04-12 2001-04-12 Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
PCT/EP2002/003663 WO2002083674A2 (fr) 2001-04-12 2002-04-03 Compositions contenant des imidazotriazinones pour application nasale

Publications (1)

Publication Number Publication Date
IL158255A0 true IL158255A0 (en) 2004-05-12

Family

ID=7681379

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15825502A IL158255A0 (en) 2001-04-12 2002-04-03 Compositions containing imidazotriazinone for nasal application

Country Status (25)

Country Link
US (2) US6740306B2 (fr)
EP (1) EP1381368A2 (fr)
JP (1) JP2004525968A (fr)
KR (1) KR20030087072A (fr)
CN (1) CN1537004A (fr)
AR (1) AR035821A1 (fr)
BG (1) BG108245A (fr)
BR (1) BR0208813A (fr)
CA (1) CA2443639A1 (fr)
CZ (1) CZ20032752A3 (fr)
DE (1) DE10118306A1 (fr)
DO (1) DOP2002000373A (fr)
EC (1) ECSP034795A (fr)
EE (1) EE200300501A (fr)
GT (1) GT200200070A (fr)
HU (1) HUP0303877A3 (fr)
IL (1) IL158255A0 (fr)
MX (1) MXPA03009314A (fr)
NO (1) NO20034556L (fr)
PE (1) PE20021035A1 (fr)
PL (1) PL363033A1 (fr)
RU (1) RU2003133143A (fr)
SK (1) SK12682003A3 (fr)
UY (1) UY27256A1 (fr)
WO (1) WO2002083674A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2449163C (fr) * 2001-05-09 2010-07-13 Bayer Healthcare Ag Utilisation nouvelle d'imidazotriazinones 2-phenyl-substituees
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
AU2005322305B2 (en) * 2004-12-23 2010-09-16 Roxro Pharma, Inc. Therapeutic compositions for intranasal administration of ketorolac
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
MX2008000087A (es) * 2005-06-23 2008-03-18 Schering Corp Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5.
AU2006299232A1 (en) * 2005-09-29 2007-04-12 Bayer Schering Pharma Aktiengesellschaft PDE inhibitors and combinations thereof for the treatment of urological disorders
WO2008151734A1 (fr) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Inhibiteurs de la phosphodiestérase (pde) destinés au traitement des troubles de l'audition
TW201002368A (en) * 2008-06-13 2010-01-16 Roxro Pharma Inc Unit dose formulations of ketorolac for intranasal administration
US8277781B2 (en) * 2009-03-13 2012-10-02 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
US8551454B2 (en) * 2009-03-13 2013-10-08 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
WO2017168174A1 (fr) 2016-04-02 2017-10-05 N4 Pharma Uk Limited Nouvelles formes pharmaceutiques du sildénafil
WO2020006606A1 (fr) * 2018-07-05 2020-01-09 Helium 3 Resources Pty Ltd Composition pharmaceutique et utilisation correspondante
SE542968C2 (en) * 2018-10-26 2020-09-22 Lindahl Anders Treatment of osteoarthritis
WO2021242913A1 (fr) * 2020-05-26 2021-12-02 Strategic Drug Solutions, Inc. Formulations et procédés de traitement du dysfonctionnement érectile

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602099A (en) * 1973-04-02 1986-07-22 Merrell Dow Pharmaceuticals Inc. Antirhinovirus agents
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6018046A (en) 1996-05-31 2000-01-25 Mochida Pharmaceutical Co., Ltd. Pyridocarbazole derivatives having cGMP-PDE inhibitory activity
GB2315673A (en) * 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
WO1998053819A1 (fr) * 1997-05-29 1998-12-03 Mochida Pharmaceutical Co., Ltd. Agent therapeutique destine a traiter l'anerection
AU9214498A (en) 1997-09-23 1999-04-12 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
UA46166C2 (uk) 1997-11-12 2002-05-15 Баєр Акцієнгезельшафт 2-фенілзаміщені імідазотриазинони як інгібітори фосфодіестерази, спосіб їх одержання та лікарський засіб на їх основі
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
WO2000000199A1 (fr) * 1998-06-26 2000-01-06 Nastech Pharmaceutical Company, Inc. Administration intranasale de citrate de sildenafil
CZ20012113A3 (cs) * 1998-12-14 2001-11-14 Cellegy Pharmaceuticals, Inc. Prostředky a způsoby pro léčbu onemocnění anorektální oblasti

Also Published As

Publication number Publication date
HUP0303877A2 (hu) 2004-03-29
EP1381368A2 (fr) 2004-01-21
JP2004525968A (ja) 2004-08-26
HUP0303877A3 (en) 2005-05-30
DE10118306A1 (de) 2002-10-17
BG108245A (en) 2005-01-31
RU2003133143A (ru) 2005-04-10
US20030022894A1 (en) 2003-01-30
PL363033A1 (en) 2004-11-15
US6740306B2 (en) 2004-05-25
CZ20032752A3 (cs) 2004-01-14
CA2443639A1 (fr) 2002-10-24
UY27256A1 (es) 2002-11-29
ECSP034795A (es) 2003-12-01
NO20034556D0 (no) 2003-10-10
WO2002083674A3 (fr) 2003-01-09
KR20030087072A (ko) 2003-11-12
WO2002083674A2 (fr) 2002-10-24
AR035821A1 (es) 2004-07-14
SK12682003A3 (sk) 2004-03-02
GT200200070A (es) 2003-01-31
EE200300501A (et) 2003-12-15
DOP2002000373A (es) 2002-11-30
NO20034556L (no) 2003-12-10
BR0208813A (pt) 2004-03-09
PE20021035A1 (es) 2002-11-29
MXPA03009314A (es) 2004-03-10
US20040248891A1 (en) 2004-12-09
CN1537004A (zh) 2004-10-13

Similar Documents

Publication Publication Date Title
IL161446A0 (en) Medicinal compositions for nasal absorption
IL162581A0 (en) Pharmaceutical compositions containing corticosteroids
IL156818A0 (en) New composition
EP1407785A4 (fr) Compositions medicinales
GB0119935D0 (en) Perfume containing composition
HK1065944A1 (en) Medicinal compositions
GB0104074D0 (en) New composition
HK1065257A1 (en) Medicinal composition
IL158255A0 (en) Compositions containing imidazotriazinone for nasal application
GB0114069D0 (en) Composition
EP1459733A4 (fr) Composition buccale
GB0107651D0 (en) Composition
GB0122113D0 (en) Composition
EP1364646A4 (fr) Composition contenant du fenofibrate
GB0115679D0 (en) Composition
GB0117305D0 (en) Composition
GB0114746D0 (en) Medicinal composition
GB0126081D0 (en) Composition
GB0121454D0 (en) Composition
AU2002304803A1 (en) Compositions containing imidazotriazinone for nasal application
EP1413314A4 (fr) Composition medicinale
GB0124008D0 (en) Compositions for inhalation
GB0123063D0 (en) Compositions for therapy
GB0126085D0 (en) Composition
IL161956A0 (en) Pharmaceutical compositions containing 5-bisoprolol